We compared the haematological parameters measured before the start of danazol therapy with those obtained after 1, 3, and 5 years of treatment-in 39 out of 145 C1-INH-HAE patients (37 with HAE type I and 2 with HAE type II) – see Fig. 1. This evidence concerns the gene SERPING1 and hereditary angioedema.